Midodrine for the treatment of vasovagal syncope (simple FAINT)

Journal of Pediatrics

Volumn 149, Issue 6, 2006, Pages 740-742

  Stewart, Julian M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; DESGLYMIDODRINE; DRUG METABOLITE; MIDODRINE; PLACEBO; UNCLASSIFIED DRUG;

CHILL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LOW DRUG DOSE; NEUROLOGIC EXAMINATION; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PATIENT POSITIONING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PRURITUS; STANDING; SUPINE POSITION; SYNCOPE; URINE RETENTION; VASOCONSTRICTION;

CHILD; HUMANS; MIDODRINE; SYNCOPE, VASOVAGAL;

EID: 33751364990     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.08.026     Document Type: Editorial

References (22)

1. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34 (2006) D668-D672
2. Stewart J.M., Munoz J., and Weldon A. Clinical and physiological effects of an acute alpha-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance. Circulation 106 (2002) 2946-2954
3. Corr P.B., Heathers G.P., and Yamada K.A. Mechanisms contributing to the arrhythmogenic influences of alpha 1-adrenergic stimulation in the ischemic heart. Am J Med 87 (1989) 19S-25S
4. Vatner S.F. Regulation of coronary resistance vessels and large coronary arteries. Am J Cardiol 56 (1985) 16E-22E
5. Gilden J.L. Midodrine in neurogenic orthostatic hypotension: a new treatment. Int Angiol 12 (1993) 125-131
6. Low P.A., Gilden J.L., Freeman R., Sheng K.N., and McElligott M.A. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. Midodrine Study Group. JAMA 277 (1997) 1046-1051
7. McClellan K.J., Wiseman L.R., and Wilde M.I. Midodrine: a review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging 12 (1998) 76-86
8. Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 46 (1996) 1470
9. Jankovic J., Gilden J.L., Hiner B.C., Kaufmann H., Brown D.C., Coghlan C.H., et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 95 (1993) 38-48
10. Piwinski S.E., Jankovic J., and McElligott M.A. A comparison of post-space flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. J Clin Pharmacol 34 (1994) 466-471
11. Ramsdell C.D., Mullen T.J., Sundby G.H., Rostoft S., Sheynberg N., Aljuri N., et al. Midodrine prevents orthostatic intolerance associated with simulated space flight. J Appl Physiol 90 (2001) 2245-2248
12. Mitro P., Trejbal D., and Rybar A.R. Midodrine hydrochloride in the treatment of vasovagal syncope. Pacing Clin Electrophysiol 22 (1999) 1620-1624
13. Perez-Lugones A., Schweikert R., Pavia S., Sra J., Akhtar M., Jaeger F., et al. Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study. J Cardiovasc Electrophysiol 12 (2001) 935-938
14. Ward C.R., Gray J.C., Gilroy J.J., and Kenny R.A. Midodrine: a role in the management of neurocardiogenic syncope. Heart 79 (1998) 45-49
15. Kaufmann H., Saadia D., and Voustianiouk A. Midodrine in neurally mediated syncope: a double-blind, randomized, crossover study. Ann Neurol 52 (2002) 342-345
16. Qingyou Z., Junbao D., and Chaoshu T. The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope. J Pediatr 149 (2006) 777
17. Strickberger S.A., Benson D.W., Biaggioni I., Callans D.J., Cohen M.I., Ellenbogen K.A., et al. AHA/ACCF Scientific Statement on the evaluation of syncope from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke and the Quality of Care and Outcomes Research Interdisciplinary Working Group and the American College of Cardiology Foundation, in collaboration with the Heart Rhythm Society; endorsed by the American Autonomic Society. Circulation 113 (2006) 316-327
18. Berkowitz J.B., Auld D., Hulse J.E., and Campbell R.M. Tilt table evaluation for control pediatric patients: comparison with symptomatic patients. Clin Cardiol 18 (1995) 521-525
19. Petersen M.E., Williams T.R., Gordon C., Chamberlain-Webber R., and Sutton R. The normal response to prolonged passive head-up tilt testing. Heart 84 (2000) 509-514
20. Sheldon R., Connolly S., Rose S., Klingenheben T., Krahn A., Morillo C., et al. Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. Circulation 113 (2006) 1164-1170
21. Miller F.G., and Rosenstein D.L. The nature and power of the placebo effect. J Clin Epidemiol 59 (2006) 331-335
22. Barsky A.J., Saintfort R., Rogers M.P., and Borus J.F. Nonspecific medication side effects and the nocebo phenomenon. JAMA 287 (2002) 622-627